Ascendis Pharma (ASND) Misses Q1 EPS by 14c, Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ASND Hot Sheet
Join SI Premium – FREE
Ascendis Pharma (NASDAQ: ASND) reported Q1 EPS of ($0.87), $0.14 worse than the analyst estimate of ($0.73). Revenue for the quarter came in at $416 thousand versus the consensus estimate of $1.37 million.
For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- XPEL, Inc. (XPEL) Tops Q3 EPS by 4c, Misses on Revenue; Offers Q4 Revenue Guidance
- Reservoir Media, Inc. (RSVR) Tops Q2 EPS by 2c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
